NASDAQ:CELC Celcuity (CELC) Stock Price, News & Analysis $134.26 -3.97 (-2.87%) As of 05/26/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Celcuity Stock (NASDAQ:CELC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Celcuity alerts:Sign Up Key Stats Today's Range$132.85▼$140.8550-Day Range$102.01▼$142.5352-Week Range$10.26▼$151.02Volume687,484 shsAverage Volume1.18 million shsMarket Capitalization$6.55 billionP/E RatioN/ADividend YieldN/APrice Target$149.30Consensus RatingModerate Buy Company Overview Celcuity, Inc. is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors. Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways. These assays are intended to serve as companion diagnostics, guiding the use of therapies such as PARP inhibitors and other targeted molecules in oncology. In addition to its core diagnostic offerings, Celcuity collaborates with pharmaceutical companies to co-develop new companion tests alongside emerging drug candidates, aiming to streamline clinical development and regulatory approval. Headquartered in Malvern, Pennsylvania, Celcuity was founded in the mid-2000s by a team of scientists and clinicians with extensive experience in cancer biology and diagnostic innovation. The company’s operations are primarily focused on the North American market, where it provides testing services through its CAP-accredited and CLIA-registered laboratory. Celcuity’s leadership team brings together expertise in biopharma partnerships, clinical diagnostics, and regulatory affairs to advance its pipeline of precision oncology solutions. AI Generated. May Contain Errors. Read More Celcuity Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreCELC MarketRank™: Celcuity scored higher than 34% of companies evaluated by MarketBeat, and ranked 635th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCelcuity has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCelcuity has a consensus price target of $149.30, representing about 11.2% upside from its current price of $134.26.Amount of Analyst CoverageCelcuity has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Celcuity's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Celcuity are expected to grow in the coming year, from ($3.96) to $0.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -34.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -34.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 122.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celcuity's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.31% of the float of Celcuity has been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 11.17, which indicates bearish sentiment.Change versus previous monthShort interest in Celcuity has recently increased by 1.40%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest9 people have searched for CELC on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows6 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,111,950.00 in company stock.Percentage Held by Insiders13.33% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Celcuity's insider trading history. Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CELC Stock News HeadlinesCelcuity: Approaching An Inflection Point With GedatolisibMay 19, 2026 | seekingalpha.comCelcuity (CELC) Q1 2026 Earnings TranscriptMay 16, 2026 | finance.yahoo.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker. | Paradigm Press (Ad)Celcuity Shares Up Following Expansion of Phase 3 Breast Cancer TrialMay 16, 2026 | marketwatch.comAnalysts Are Bullish on Top Healthcare Stocks: Celcuity (CELC), Rubicon Organics (ROMJF)May 16, 2026 | theglobeandmail.comCelcuity outlines VIKTORIA-2 expansion while targeting July 17 FDA decision for gedatolisibMay 16, 2026 | msn.comAssessing Celcuity (CELC) Valuation After Positive VIKTORIA 1 Data And Upcoming FDA DecisionMay 16, 2026 | finance.yahoo.comInsider Selling: Celcuity (NASDAQ:CELC) Director Sells 9,000 Shares of StockMay 7, 2026 | insidertrades.comSee More Headlines CELC Stock Analysis - Frequently Asked Questions How have CELC shares performed this year? Celcuity's stock was trading at $99.74 at the beginning of 2026. Since then, CELC shares have increased by 34.6% and is now trading at $134.26. How were Celcuity's earnings last quarter? Celcuity, Inc. (NASDAQ:CELC) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. Read the conference call transcript. When did Celcuity IPO? Celcuity (CELC) raised $22 million in an IPO on Tuesday, September 19th 2017. The company issued 2,400,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. Who are Celcuity's major shareholders? Top institutional investors of Celcuity include Bank of America Corp DE (1.46%), Jennison Associates LLC (0.48%), Candriam S.C.A. (0.48%) and Walleye Capital LLC (0.22%). Insiders that own company stock include David Dalvey and Richard E Buller. View institutional ownership trends. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celcuity investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and ServiceNow (NOW). Company Calendar Last Earnings5/14/2026Today5/26/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CELC's financial health is in the Green zone, according to TradeSmith. CELC has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:CELC CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees40Year Founded2012Price Target and Rating Average Price Target for Celcuity$149.30 High Price Target$189.00 Low Price Target$60.00 Potential Upside/Downside+11.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$177.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-244.61% Return on Assets-50.22% Debt Debt-to-Equity Ratio6.04 Current Ratio12.31 Quick Ratio12.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book122.05Miscellaneous Outstanding Shares48,766,000Free Float42,265,000Market Cap$6.55 billion OptionableOptionable Beta0.09 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CELC) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
